Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma

Archives of Ophthalmology

Volumn 130, Issue 12, 2012, Pages 1608-1611

  El Sawy, Tarek ^a   Sabichi, Anita L ^a   Myers, Jeffrey N ^a   Kies, Merrill S ^a   William, William N ^a   Glisson, Bonnie S ^a   Lippman, Scott ^a   Esmaeli, Bita ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; ERLOTINIB;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE INCREASE; EXOPHTHALMOS; EYE MOVEMENT DISORDER; FEMALE; FOLLOW UP; HUMAN; MALE; ORBITAL SQUAMOUS CELL CARCINOMA; PAIN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; VISUAL DISORDER;

EID: 84871230240     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2012.2515     Document Type: Article

References (6)

1. Stewart JSW, Cohen EEW, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol. 2009;27(11):1864-1871.
2. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116-1127.
3. Bauman JE, Eaton KD, Martins RG. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol. 2007;143(7):889-892. (Pubitemid 47076487)
4. Lewis CM, Glisson BS, Feng L, et al. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012;18(5):1435-1446.
5. Maubec E, Petrow P, Scheer-Senyarich I, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011;29(25):3419-3426.
6. Shepler TR, Prieto VG, Diba R, Neuhaus RW, Shore JW, Esmaeli B. Expression of the epidermal growth factor receptor in conjunctival squamous cell carcinoma. Ophthal Plast Reconstr Surg. 2006;22(2):113-115. (Pubitemid 44474508)